| Literature DB >> 34141084 |
Haibin Zhou1, Longchuan Bai1, Renqi Xu1, Donna McEachern1, Krishnapriya Chinnaswamy1, Ruiting Li1, Bo Wen1, Mi Wang1, Chao-Yie Yang1, Jennifer L Meagher1, Duxin Sun1, Jeanne A Stuckey1, Shaomeng Wang1.
Abstract
Signal transducer and activator of transcription 3 (STAT3) is an attractive cancer therapeutic target. We report herein our extensive in vitro and in vivo evaluations of SD-91, the product of the hydrolysis of our previously reported STAT3 degrader SD-36. SD-91 binds to STAT3 protein with a high affinity and displays >300-fold selectivity over other STAT family protein members. SD-91 potently and effectively induces degradation of STAT3 protein and displays a high selectivity over other STAT members and >7000 non-STAT proteins in cells. A single administration of SD-91 selectively depletes STAT3 protein in tumor tissues with a persistent effect. SD-91 achieves complete and long-lasting tumor regression in the MOLM-16 xenograft model in mice even with weekly administration. Hence, SD-91 is a potent, highly selective, and efficacious STAT3 degrader for extensive evaluations for the treatment of human cancers and other diseases for which STAT3 plays a key role.Entities:
Year: 2021 PMID: 34141084 PMCID: PMC8201759 DOI: 10.1021/acsmedchemlett.1c00155
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.632